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 Chapter 1              
 Introduction  
 
The main purpose of the Final Project is to show how to conduct one veterinary 
experiment. It can be divided into three phrases: planning, implementation, analysis. These 
three phrases should be complementary from the begining to the end of the veterinary 
experiment. During the planning is important to set goals that will be pursued and the 
instruments that will be used. 
During the implementation of the experiment the most important thing is the selection of 
the units and the methods that are used. 
After passing these two phrases comes the last phrase analysis of the data. This stage 
includes various statistical procedures, analysis and methods so we can make conclusion 
and summaries, and describe the characteristics. 
The main problem in this Final Project is to study the effect of two medicaments on a 
particular population and to compare the effects they produce on treated experimental 
units. 
In the Final Project we will keep the requirements listed in “Guideline on Statistical 
Principles for veterinary clinical trials”. 
We will use the software package Statistica to make the conclusions in the end of the Final 
Project. 
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Chapter 2 
Guideline on Statistical 
Principles for Veterinary Clinical Trials 
 
The focus of this guideline is on statistical principles. In this guideline the role of statistics 
in clinical trial design and analysis is acknowledged as essential. The guideline is written 
primarily to harmonise the principles of statistical methodology applied to clinical trials. 
The guideline is intended to give directions to sponsors in the design, conduct, analysis and 
evaluation of clinical trials of an investigational veterinary product in the context of its 
overall clinical development. 
 
2.1 Considerations for Overall Clinical Development 
 
The broad aim of the process of clinical development of a veterinary medicinal product is 
to determine whether there is a dose at which the product can be shown to be 
simultaneously safe and effective. Satisfying these broad aims usually requires an ordered 
programme of clinical trials, each with its own specific objectives. This should be specified 
in an ordered development plan, with appropriate decisions points and flexibility to allow 
modification as knowledge accumulates. 
Depending on the aim of the trial, it can be classed in one of the following three categories: 
confirmatory, exploratory, or composite. 
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2.2 Type of Clinical Trials 
2.2.1 Confirmatory trial 
 
Confirmatory trials can concern dose determination trials, dose confirmation trials as well 
as controlled field trials. 
Confirmatory trials : 
• Are controlled. 
• Have an agreed protocol written and signed before the study begins. 
• Test a hypothesis that is started in advance. 
• Only address a limited number of questions. 
• Are necessary to provide firm evidence of efficacy and/or in-use safety. 
• Estimate with due precision the size of the effects attributable to the treatment 
under evaluation and relates these effects to their clinical significance. 
• Are justified in terms of their design and other statistical aspects such as planned 
analysis. 
• Clearly and definitively answer each question relevant to support the started 
hypothesis. 
• Explain the generalisation from the chosen study animal population. 
• Produce robust results.  
 
  2.2.2 Exploratory Trial  
 
The rationale and design of confirmatory trials often rests on earlier clinical work 
carried out in a series of exploratory studies. Exploratory trials are: 
• Precursors to confirmatory trials. 
• Also have clear objectives. 
• Such objectives may not always lead to simple tests of predefined hypotheses. 
• Sometimes require data exploration during analysis. 
• The choice of the hypothesis may be data dependant. 
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2.2.3 Composite trial  
 
It may have both confirmatory and exploratory   aspects.  
The protocol should make a clear distinction between those aspects of the trial which are 
confirmatory and those which are exploratory. 
 
2.3 Population  
 
In the earlier phases of new product development the choice of subjects for a clinical trial 
may be heavily influenced by the wish to maximise the chance of observing specific 
clinical effects of interest, and hence. They may come from a very narrow sub-group of the 
total animal patient population for which the product may eventually be indicated. No 
individual clinical trial can be expected to be totally representative of the future target 
population because of potential influences of, for example, geographical location, timing, 
animal husbandry, and local veterinary clinical practices. Wherever possible the influence 
of such confounding factors should be taken into account and subsequently discussed 
during the interpretation of the trial results. 
 
2.4 Primary and Secondary Variables 
 
2.4.1 Primary Variable 
The primary variable should be the variable capable of providing the most clinically 
relevant and convincing evidence directly related to the primary objective of the trial. 
Generally there should only be one primary variable. 
The variable should be reliable and validated and derived from experience in previous 
studies or in published scientific literature. These should be sufficient evidence that the 
chosen primary variable can provide a valid and reliable measure of some clinically 
relevant and important clinical benefit in the study animal population as defined by the 
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inclusion and the inclusion criteria. This is generally variable used to estimate the sample 
size. 
 
2.4.2 Secondary Variables 
 
Secondary Variables are either supportive measurements related to the primary objective or 
measurements of effects related to the secondary objectives. Their pre-definitions in the 
protocol is also important. 
In some situation it may be useful to combine the multiple measurements into a single or 
“composite” variable using the pre-defined algorithm. The method of combining the 
multiple measurements should be specified in the protocol. Combining multiple 
measurements addresses the multiplicity problem without requiring adjustment for multiple 
comparisons. 
 
2.5 Design Techniques to Avoid Bias 
 
Other sources of bias arise during the conduct and analysis of a clinical trial. The two most 
important design techniques for avoiding bias in clinical trials are blinding and 
randomisation. 
 
2.5.1 Blinding 
 
Blinding is intended to limit the occurrence of conscious and unconscious bias in the 
conduct and interpretation of a clinical trial which may arise from the knowledge of 
specific treatment a study animal may be receiving or is about to receive. The essential aim 
is to prevent identification of the treatment until all such opportunities for bias have passed. 
Therefore is important to try achieving optimum blinding (full-blinded story). 
A full-blinded trial is one in which the investigator and sponsor stuff  involved in the 
treatment or clinical evaluation, the owner or carers of the study animals, or any other 
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persons associated with administrating the treatment are unaware of the treatment received 
by the study animals. 
 
 
2.5.2 Randomisation 
 
It also tends to produce treatment groups in which the distributions of prognostic factors 
(known and unknown) are similar. The randomisation schedule of a clinical trial 
documents the random allocation of treatments to study animals. 
 
 
2.6 Study Design Considerations 
2.6.1 Parallel Group Design 
 
The most common clinical trial design for confirmatory trials is the parallel group design in 
which study animal are randomised to one of two or more arms, each arm being allocated a 
different treatment. These treatments will include the investigational product at one or 
more doses, and generally one or more control treatment, such as placebo and/or an active 
comparator. 
 
2.6.2 Cross-over design 
  
In the cross-over design, each study animal is randomised to a sequence of two or more 
treatments, and hence acts as its own control for treatment comparisons. The most common 
use of cross-over design is to demonstrate the bioequivalence. 
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2.6.3 Factorial Designs 
 
In a factorial design two or more treatments are evaluated simultaneously in the same set of 
subjects through the use of varying combinations of the treatments. The simplest examples 
is the 2x2 factorial design in which study animals are randomly allocated to one of the four 
possible combinations of two treatments, A and B say. These are: A alone; B alone; both A 
and B; neither A nor B. In many cases this design is used for the specific purpose of 
examining the interaction of A and B. The statistical test of interaction is model dependent 
and may lack power to detect an interaction if the sample size was calculated based on the 
test for main effects. 
 
  
 2.7   Type of comparison  
 
All the studies should be designed to control the risk of concluding erroneously what they 
are supposed to demonstrate. 
 
2.7.1 Show Superiority  
 
Superiority studies are designed to detect a difference. Scientifically, efficacy is more 
convincingly established by demonstrating superiority to an active control treatment or by 
demonstrating a dose response relationship. 
 
2.7.2 Trials to show Equivalence or Non-inferiority 
 
Active control equivalence or non-inferiority trials may also incorporate a placebo, thus 
pursuing multiple goals in one trial, for example, establishing superiority to placebo and 
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hence validating the study design and evaluating the study design and evaluating the degree 
of similarity of efficacy and safety to the active comparator. 
 
 
2.7.3 Dose-response Designs    
 
Dose response studies may serve a number of objectives, amongst which the following are 
of particular importance: 
The confirmation of efficacy: the investigation of the shape and location of the dose-
response curve; the estimation of an appropriate starting dose; the identification of optimal 
strategies for individual dose adjustments; and/or the determination of a maximal dose 
beyond which additional benefit would be unlikely to accur. 
 
 
2.7 Interim Analysis and Early Stopping  
 
The goal of such an interim analysis is to stop the trial early if the superiority of the 
treatment under study is clearly established. If the demonstration of a relevant treatment 
difference has become unlikely or if unacceptable adverse effects are apparent. 
 
2.8 Data Analysis  
 
• Definition of the experimental unit. 
• Hypothesis to be tested. 
• Treatment effect(s) to be estimated. 
• Statistical model. Test(s) and constructions of confidence intervals. 
• Justification of the use of one- or two-sided tests. 
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• Use of covariate(s). 
• Significance threshold. 
• Power (1-β) and other assumptions used in sample size estimation. 
• Set of experimental units to be included in the analysis. 
• Planned data transformations. 
• Bayesian estimates. 
• Reporting of summary data. 
• Comparison of groups at baseline. 
• Alternative methods to be used in case of expected problems 
 
 
3. Analysis of Variance  
 
Analysis of variance can be viewed as a special case of multiple regression where the 
explanatory variables are entirely qualitative. 
 
3.1 One-way analysis of Variance  
 
One way analysis of variance can be viewed as a special case of bivariate analysis.The two 
variables X and Y, whose relationship is to be studied, represent a qualitative variable Y 
and a quantitative variable X. The variable Y is assumed to be a continuous random 
variable with density f(Y). The variable X is assumed to be a classification variable with g 
categories. The interrelationship between the two variables therefore involves a comparison 
of distribution of Y among the g categories of X. Such analyses may involve comparison of 
distribution parameters such as means or variances or may involve direct comparison of the 
density functions. The procedures that involve a comparison of the means have 
traditionally been referred to as analysis of variance. 
The term analysis of variance was first applied to these procedures because the statistical 
tests involve comparisons of various sums of squares or variation. The classification 
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variable X is usually referred to as a factor and the categories of X are called levels. The 
one-way analysis of variance is also called a single factor analysis of variance. 
Many scientific studies include the comparison of the properties of items which have been 
classified into types of brands or categories. Examples of such categories include varieties 
of an agricultural product such as corn, various brands of a consumer good such as soap 
and various methods of carrying out a task such as treating a patient or advertising a 
product. 
 
3.1.1 The Sampling Model 
 
One column of the data matrix contains observations on a continuous random variable Y. 
A second column of the data matrix contains observations on a classifications variable X 
which classifies the n individuals or objects into g categories or groups. The X variable 
assumes one of the g integer values 1, 2, 3,…,g. We can view the n individuals as a random 
sample from a populations which after classification according to X resulted in totals of 
1 2, ,...., gn n n  observations from the g groups respectively. 
The means for the distributions of Y for the g groups are denoted by 1 2, ,...., gµ µ µ , while 
the variances are assumed to be homogeneous with magnitude 2σ .The distribution of Y is 
assumed to be normal for each group. 
The model describing the behaviour of the Y observations may be written as: 
ij j ijy µ ε= + ,              1, ji n= ; 1,j g=  
2(0, )ij Nε σ∈  
Where ijε  represents a random variable with mean 0 and variance 2σ . By assumption the 
ijε are mutually independent. This model is sometimes called a cell means model. Under 
the assumption of homogeneity of variance the best unbiased estimator of jµ is . jy .The 
model therefore can be written: 
.. ( )ij ij jjy y y y= + −       1, 2,....., ji n=        1, 2,....,j g=  
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With . jy  as an estimator of jµ  and .( )ij jy y− = ije as an estimator of ijε .The predicted 
values for ijy  from this model are .ˆij jy y= . 
 
 
Sums of Squares 
 
The total variation in Y over the sample, SST or the total sum of the squares,is described 
by: 
 
 
2
..
1 1
( )
jng
ij
j i
SST y y
= =
= −∑ ∑  
The Total Sum of Squares measures the variation in the Y values around the grand mean or 
overall mean given by  
..
1 1
jng
ij
j i j
y
y
n= =
=∑ ∑                                                            where 
1
g
j
n
n n
=
=∑  
The variation explained by the fitted model is given by SSA, the sum of squares among 
groups. This Sum of Squares Among Groups measures the variation among the group 
means and is determined as: 
2 2 2
.. . .. . ..
1 1 1 1 1
ˆ( ) ( ) ( )
j jn ng g g
ij j j j
j i j i j
SSA y y y y n y y
= = = = =
= − = − = −∑ ∑ ∑∑ ∑   (3.4) 
 
For all g groups the total within-group sum of squares is given by: 
2
.
1 1
( )
jng
ij j
j i
SSW y y
= =
= −∑∑    (3.5) 
It is easily demonstrated that  
SST SSA SSW= +  
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Estimation of 2σ  
Under the assumption of homogeneity of variance the best unbiased estimator is given by:  
2
1 ( 1)
SSAs
g
=
−  
2
2
SSWs
n g
=
−  
We apply the F statistic: 
    
2
1
2
2
sF
s
=     (3.6) 
The F statistic has Fisher’s distribution with (g-1) and (n-g) degrees of freedom. 
 
Hypothesis  
 
0 1 2 ... gH µ µ µ= = = =  
1H : not all gµ  are equal. 
Order to except or reject 0H calculate the corresponding  critical region  at using  α as the 
level of significance and then compare to our F statistic from (3.6). If the value form the 
test statistic falls in the critical region  reject 0H , otherwise do not reject 0H . 
 
3.1.2 Group Effects Models 
 
An alternative model that is commonly used is the group effects model given by:  
ij j ijy µ α ε= + +         1, 2,.....,i n=        1, 2,....,j g=  (3.7) 
Where  
1
0
g
j
j
α
=
=∑ ,  and the ijε ∈  2(0, )N σ . 
The grand mean or overall mean isµ , jµ is equivalent to  
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( )jµ α+ ,   1, 2,....,j n=  where µ is the grand mean or overall mean, 
1
g
j
j g
µ α
µ
=
+
=∑ . 
A test of 0 1 2 ... gH µ µ µ= = = =  is therefore equivalent to a test of 
0 1 2 ... gH α α α= = = = . The minimum variance unbiased estimators of the parameters 
µ  and jα  
J=1, 2….g are given by ..y and . ..( )jy y− , j=1,2,…..,g respectively. 
 
 
 
3.1.3 Multiple comparisons 
 
If the null hypothesis 0H of equal means is rejected, a follow- up questions would be” 
which groups have different means?” Procedures for the comparison of cell means are 
called multiple comparison procedures. This section summarizes a variety of procedures 
commonly used to compare means. 
 
LSD(Least Significant Difference) method 
 
For any two groups j  and l  a 100(1-α)% confidence interval for ( )j lµ µ− may be 
constructed using a t  distribution. A 100(1-α)% confidence interval for ( )j lµ µ−  is given 
by: 
8
1/2
. . /2;( )
1 1( )j l n g
j l
y y t
n nα −
 
− ± + 
  
 
Where 
2
( )
SSWs
n g
=
−
. If the interval includes 0 the means are said to be not significantly 
different at the α  level. 
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This procedure is commonly called the least significant difference or the LSD procedure. 
The problem with multiple comparisons such as LSD is that if the numbers of groups g, is 
large there are a total of 
1
2
gg − such comparisons. If a 5% type I error probability is used, 
we can expect 
1(0.05)
2
gg −  differences to appear significant even if there aren’t any real 
differences. The type I error α  in this case is the per comparison error but not the 
experimentwise error. 
The experimentwise type I error rate refers to the probability of finding at least one 
significant difference over the complete set of all comparisons. 
 
Sheffe  
 
The most conservative approach to judging differences among means employs a result 
established by Scheffe(1959). For a paired comparison among means jµ and lµ a 
100(1 )%α−  confidence interval is given by  
1
2
. . ;( 1)( )
1 1( ) ( 1)j l g n g
j l
y y s g F
n nα − −
  
− ± − +  
    
 
This method guarantees that the experimenwise error rate is controlled at level α  for all 
possible paired comparisons among means. 
 
Bonferroni  
 
An approximate procedure for controlling the experimentwise error rate at α .In the case 
of the g means there are total of 1
2
gg p− = different pairs to be compared. Letting JA                       
1, 2,....j p=  denote the event that the j -th pair of means are declared equal we may 
write the probability that all p pairs are declared equal as 1 2[ , ... ]pP A A A .For an 
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experimentwise rate of α we would like to have 1 2(1 ) [ , ,... ]pP A A Aα− = .By the 
Bonferroni inequality: 
1 2
1
[ , ..... ] 1 ( )
p
p J
j
P A A A P A
=
≥ −∑  
If we assume that 0( )jP A α=  is constant for 1, 2,....,j p= , 
We have 0(1 ) 1 pα α− ≥ − and hence 0 p
αα ≥  or 0pα α≤ . For a given α ,the 
Bonferroni approach uses 0
( 1) / 2g g
αα =
−
, 
And therefore uses 0
2;( )n g
t
α
−
 as the critical value of the test statistics rather than 
2;( )n g
t
α
−
 
as in the case of LSD procedure. 
The Bonferroni procedure is useful for making pairwise comparisons when the F-test of 
equality of means did not reject the equality hypothesis. 
 
 
3.2 Two- way analysis of Variance  
 
The relationship between a quantitative variable Y and a qualitative variable X was studied 
using one-way analysis of variance. In this sections a second qualitative variable say Z is 
introduced. The categories of the two qualitative variables jointly define a set of cells and 
the variation of in these cell means for the variable Y is to be studied. 
 
3.2.1 The Randomized Block Design Model 
 
The most commonly used model for the randomized block design is given by  
ij i j ijy µ β α ε= + + +       1,i b=      1,j g=  
Where  
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1
0
g
j
j
α
=
=∑                     
1
0
b
j
i
β
=
=∑  
 
And the ijε are independent and identically distributed ,  
2(0, )N σ . The best linear unbiased estimators of iµ , iβ  and jα are given by  
..ˆ yµ = ,    . ..iˆ iy yβ = −  and            . ..ˆ j jy yα = −  
Where  
..
1 1
1 gb
ij
i j
y y
bg = =
= ∑∑ ,             .
1
1 b
j ij
i
y y
b =
= ∑             .
1
1 g
i ij
j
y y
g =
= ∑  
 
 
 
Sums of squires  
 
22 2
.. ..
1 1 1 1
( )
g gb b
ij ij
i j i j
SST y y y gby
= = = =
= − = −∑∑ ∑∑      (3.12) 
2
22
. .. . ..
1 1
( )
g g
j j
j j
SSA b y y b y gby
= =
= − = −∑ ∑          (3.13) 
2
22
. .. . ..
1 1
( )
b b
i i
j i
SSB g y y g y gby
= =
= − = −∑ ∑      (3.14) 
SSE SST SSA SSB= − −            
2 2 22 2
. . .. . .
1 1 1 1 1 1
( )
g g gb b b
ij j i ij j i
i j i j j i
SSE y y y y y b y g y gby
= = = = = =
= − − + = − − +∑∑ ∑ ∑ ∑ ∑  
 
 
 18 
3.2.2 The Two Factor Factorial 
 
If the relationship between a dependent quantitative  variable Y and two qualitative 
variables is of interest then a two factor model is required. We assume that the first factor 
X has g levels while the second factor Z has b levels. The cross classifications of the two 
factors therefore has bg cells.We shall assume that c observations are randomly selected 
from each of the bg cells yielding a total of n=bgc observations. 
Alternatively, a total of n experimental units are randomly assigned to the bg treatment 
combinations, in such a way that each combination is observed on c occasions. 
The balanced two-way model is usually given by: 
 
( )ijh j j ij ijhy µ α β αβ ε= + + + + ,   1,i b= ; 1,j g= ; 1,h c=  
Where  
1 1 1 1
( ) ( ) 0
g gb b
j j ij ij
i j i j
β α αβ αβ
= = = =
= = = =∑ ∑ ∑ ∑  
And the ijhε  are mutually independent 2(0, )N σ . 
The parameters ( )ijαβ  are called interaction parameters. 
The best linear unbiased estimators of the parameters are given by  
. . ...ˆ j jy yα = −  
.. ...iˆ iy yβ = −  
.ˆij ijyµ =  
And  
( ). .. . . ... .. ... . . ... ...ˆˆ( ) ( ) ( )ij ij i j ij i jy y y y y y y y y yαβ  = − − + = − − − − −  For the balanced 
two-way design three independent hypothesis tests can be carried out using an F- statistic. 
The hypotheses are : 
01 1 2: ..... 0gH β β β= = = =  
02 1 2: ..... 0bH α α α= = = =  
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03 11 12: ( ) ( ) ..... ( ) 0bgH αβ αβ αβ= = = =  
The sum of squares are given by: 
( )2 22... ...
1 1 1 1 1 1
g gb c b c
ijh ijh
i j h i j h
SST y y y bgc y
= = = = = =
= − = −∑ ∑ ∑ ∑ ∑ ∑  
( )
2
2 2
. . ... . . ...
1 1
g g
j j
j j
SSA bc y y bc y bgc y
= =
= − = −∑ ∑  
( )
2
2 2
.. ... . . ...
1 1
b b
i j
i i
SSB gc y y gc y bgc y
= =
= − = −∑ ∑  
( )2 2 2 2 2. .. . . ... . . . .. ...
1 1 1 1 1 1
g g gb b b
ij i j ij j i
i j i j j i
SSI c y y y y c y bc y gc y bgc y
= = = = = =
= − − + = − − +∑ ∑ ∑∑ ∑ ∑  
( )
2
22
. .
1 1 1 1 1 1 1 1
g g gb c b c b
ijh ijhij ij
i j h i j h i j
SSE y y y c y
= = = = = = = =
= − = −∑∑∑ ∑∑∑ ∑∑  
 
 
4. Statistical Analysis of the Effects of Two Medicaments 
 
In this chapter we will examine the effects of two medicaments Tiamulin – produced by 
“Novartis” pharmaceutical company and Tiamulin – produced by “Balcanpharm” 
pharmaceutical company on an experimental population. The research teams have treated 
the animals with these two medicaments and one control which is called placebo.We have 
three types of symptoms: diarrhoea,dehydration,appetite.The data are grouped in one table 
called -major matrix of data. 
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Description of the data matrices  
  Main Data Matrix  
 
The main matrix of data consists of 10 columns: 
The first column is named:Type.This column contains three types of symptoms studied: 
diarrhoea,dehydration,appetite. 
The second column is named:Weight.This column contains a number of objects excibiting 
certain symptoms. 
The third column is named:Tiamulin.It contains the two medicaments and the control 
product. 
Day1,Day2,……Day7 consists levels of a symptom of the day. 
 
Secondary Data Matrices 
 
To obtain secondary data matrices are removed columns and rows that do not participate in 
a particular analysis.  
In conducting an analysis of the impact of drugs on dehydration symptom data were deleted 
two other symptoms that are irrelevant to this analysis. 
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4.1 Analysis of active medicaments with 
      including placebo 
4.1.1 Impact and comparison of medicaments 
according to the symptom “Diarrhea”. 
 
 
 
Figure 4.1: Effect of medicaments Tiamulin on the symptom “Diarrhea”. 
 
 
This figure reflected the impact of two medicaments Tiamulin produced by “Novartis” and 
Tiamulin –“Balcanpharm” on the symptom “Diarrhea”during different days of the 
treatment.We found that the impact of factor Tiamulin has a statistically significant 
effect.The level of agreement (p-level) is less than 0.0001.In this case it has a probability to 
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make a mistake, when we accept the hypothesis that factor effects the response,but this is 
not so. 
During the first day of the treatment,the effect of Tiamulin- Novartis is slightly greater than 
that of other medicament.During the second day the impact of the medicament Tiamulin-
Balcanpharma is more strong. 
It is mentioned after the third day but with less force. 
We can see these features in the following table: We use The Method of Sheffe to see 
whether the effects of both medicaments is equal to the control group and in which days is 
the same impact.We see the results on the five tables. 
During the second day we see that the difference between the impact of the medicaments 
“Novartis” and ”Balcanpharm”is not statistically significant.We can see demonstrated 
equivalence for the first,third,fourth and fifth day. 
 
 
Testing equivalence: 
 
 
 
Fist Day: 
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Second Day: 
Scheffe Test; Variable: DAY2 (DATAdia.STA)
Marked differences are significant at p < ,05000
TIAMULIN
{1}
M=,61905
{2}
M=,72222
{3}
M=,46825
Novartis {1}
Balcanpharm {2}
Placebo  {3}
0,534445 0,262951
0,534445 0,023178
0,262951 0,023178  
 
Third Day: 
 
 
Fourth Day: 
Scheffe Test; Variable: DAY4 (DATAdia.STA)
Marked differences are significant at p < ,05000
TIAMULIN
{1}
M=,06349
{2}
M=,10317
{3}
M=,92063
Novartis {1}
Balcanpharm {2}
Placebo {3}
0,872524 0,000000
0,872524 0,000000
0,000000 0,000000  
 
 
Fifth Day: 
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4.1.2 Impact and comparison of medicaments 
according to the symptom “Dehydration”. 
   
Figure 4.2: Effect of medicaments Tiamulin on the symptom “Dehydration”. 
This figure reflected the impact of two medicaments Tiamulin produced by “Novartis” and 
Tiamulin –“Balcanpharm” on the symptom “Dehydration”during different days of the 
treatment. We found that the impact of factor Tiamulin has a statistically significant 
effect.The level of agreement (p-level) is less than 0.0001.We see that the antibiotic 
Tiamulin-“Balcanpharm” has a predominantly effect during the first three days and it is 
more noticeable in the second.On the fourth day the symptom no longer occurs. We can see 
these features in the following table: 
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Testing equivalence 
We use again the method of Scheffe.The results are presented in tables 4.8-4.11. 
During the first day we noticed that differences in impact between the medicaments and 
controller product are not statistically significant.We can see that there is a equivalence 
between the two medicaments .For the second day we can say that there is not equivalence 
between the two drugs and there is not statistically significant difference.For the past three 
days the effects of both two medicaments is equivalent. 
 
 
Multivariate Tests of Significance (Dehidrataciq_Tiamulin-Placebo.sta
Sigma-restricted parameterization
Effective hypothesis decomposition
Effect
Test Value F Effect
df
Error
df
p
Intercept
Тiamulin/Placebo
Wilks 0,482603 79,54942 5 371 0,00
Wilks 0,437595 37,96766 10 742 0,00  
 
 
First Day: 
 
 
Second Day: 
Scheffe Test; Variable: DAY2 (DATAdehi.STA)
Marked differences are significant at p < ,05000
TIAMULIN
{1}
M=,07937
{2}
M=,19841
{3}
M=,46825
Novartis {1}
Balcanpharm {2}
Placebo {3}
0,203233 0,000000
0,203233 0,000320
0,000000 0,000320  
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Third Day: 
 
Fourth Day: 
 
 
 
Fifth Day: 
Scheffe Test; Variable: DAY5 (DATAdehi.STA)
Marked differences are significant at p < ,05000
TIAMULIN
{1}
M=0,0000
{2}
M=0,0000
{3}
M=1,0952
Novartis{1}
Balcanpharm {2}
Placebo  {3}
1,000000 0,00
1,000000 0,00
0,000000 0,000000  
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4.1.3 Impact and comparison of medicaments 
according to the symptom “Apetite”. 
 
 
 
 
 
 
 
Figure 4.2: Effect of medicaments Tiamulin on the symptom “Apetite”. 
 
We found that the impact of factor Tiamulin has a statistically significant effect.The level of 
agreement (p-level) or significance probability  is less than 0.0001.During the first day the 
effect of the antibiotic “Tiamulin-Novartis” is strong.During the second day the effect of the 
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antibiotic “Tiamulin-Balcanpharm” is much stronger.And during the following days of the 
treatment there is almost no difference. We can see these features in the following tables: 
 
 
Multivariate Tests of Significance (Apetit_Tiamulin-Placebo.sta
Sigma-restricted parameterization
Effective hypothesis decomposition
Effect
Test Value F Effect
df
Error
df
p
Intercept
Tiamulin/Placebo
Wilks 0,511770 70,78698 5 371 0,00
Wilks 0,454405 35,87343 10 742 0,00  
 
Testing equivalence: 
We use again the method of Scheffe.The results are presented in tables 4.13 -4.16.During 
the first day there is a statistically significant difference in the effect of both drugs.For the 
second day we can say that there is no statistically significant difference but the 
equivalence is weak.For the other days the impact of both drugs is equivalent. 
 
 
 
 
 First Day: 
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Second Day: 
 
 
 
Third Day: 
 
 
Fourth and Fifth Day: 
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4.2 Analysis of the two medicaments without 
including placebo 
 
The Impact of the two medicaments: 
Here we are interested in the effects of Tiamulin factor and differences in the effects of 
both drugs on the three symptoms together. 
We can see the results in these tables. 
We notice that the main differences are in the first and second day after application of 
medicaments. 
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Testing equivalence: 
To follow exactly in which symptoms and in which days are the differences we use a 
method of Sheffe.We can see this on table 4.19.Statistically significant symptoms on the 
second day are “dehydratation” on the second day and “appetite” on the first and second 
day after taking the medicaments. 
 
Breakdown Table of Descriptive Statistics (Diariq-Dehidrataciq-Apetit_Tiamulin.st
N=756 (No missing data in dep. var. list)
Tiamulin Day 1
Means
Day 2
Means
Day 3
Means
Day 4
Means
Day 5
Means
Novartis 0,830688 0,283069 0,103175 0,021164 0,002646
Balcanpharm 0,756614 0,404762 0,132275 0,034392 0,000000
All Grps 0,793651 0,343915 0,117725 0,027778 0,001323  
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Guideline of both medicaments effects on the 
three symptoms 
Figure 4.5:Effects of both medicines on the three 
symptoms.
 
 
 
We use the two-factor analysis of variance where the two factors are “Symptom” and 
“Tiamulin”.We can see this on the table 4.17. 
There is no statistically significant effect (A*B). 
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The effect of the two medicaments on the three symptoms is the 
same.
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4.3 Summaries of the results 
 
 
Analysis of the medicaments with including a placebo: 
 
1.The influence of the two medicaments-Tiamulin –“Novartis” and Tiamulin-
“Balcanpharm” is statistically significant. 
2.The impact of both two drugs is equivalent in the last three days of the therapy. 
3.There are differences in symptoms on the second day and statistically significant 
difference. 
 
Analysis of the medicaments without placebo: 
 
1.There is statistically significant difference on the symptoms “Dehydration” on the second 
day and “Appetite” on the first and second day. 
2.The effects of the active medicaments is similar. 
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Chapter 5 
Conclusion 
 This final project introduced us the concrete application of analysis of variance-assesing 
the effect of two drugs-“Tiamulin”-Novartis and  
“Tiamulin”-Balcanpharm.We used the method of Sheffe to see their similarities  and 
differences in their impact. 
We acquainted with the basic European rules and standards which must be respected. 
The final project could be developed in different directions –to determine the maximum 
and minimum optimal dose of the medication,to check for any side effects of the 
medicaments,to determine what combinations are beneficial and t.e. 
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1
TYPE
2
WEIGHT
3
TIAMULIN/PLAC
EBO
4
DAY1
5
DAY2
6
DAY3
7
DAY4
8
DAY5
9
DAY6
10
DAY7
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
DIA 1,000 NOVARTIS 3,000 2,000 2,000 1,000 0,000
DIA 2,000 NOVARTIS 2,000 1,000 1,000 0,000 0,000
DIA 3,000 NOVARTIS 2,000 1,000 0,000 0,000 0,000
DIA 4,000 NOVARTIS 1,000 1,000 0,000 0,000 0,000
DIA 5,000 NOVARTIS 1,000 1,000 0,000 0,000 0,000
DIA 6,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
DIA 1,000 NOVARTIS 1,000 1,000 1,000 1,000 0,000
DIA 2,000 NOVARTIS 1,000 1,000 1,000 0,000 0,000
DIA 3,000 NOVARTIS 1,000 2,000 1,000 0,000 0,000
DIA 4,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
DIA 5,000 NOVARTIS 2,000 0,000 0,000 0,000 0,000
DIA 6,000 NOVARTIS 0,000 0,000 0,000 0,000 0,000
DIA 1,000 NOVARTIS 2,000 1,000 1,000 0,000 0,000
DIA 2,000 NOVARTIS 2,000 1,000 1,000 0,000 0,000
DIA 3,000 NOVARTIS 1,000 1,000 0,000 0,000 0,000
DIA 4,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
DIA 5,000 NOVARTIS 0,000 0,000 0,000 0,000 0,000
DIA 6,000 NOVARTIS 0,000 0,000 0,000 0,000 0,000
DIA 1,000 NOVARTIS 3,000 2,000 2,000 1,000 1,000
DIA 2,000 NOVARTIS 3,000 2,000 1,000 1,000 0,000
DIA 3,000 NOVARTIS 2,000 2,000 1,000 1,000 0,000
DIA 4,000 NOVARTIS 1,000 1,000 1,000 0,000 0,000
DIA 5,000 NOVARTIS 1,000 1,000 0,000 0,000 0,000
DIA 6,000 NOVARTIS 1,000 1,000 0,000 0,000 0,000
DIA 1,000 NOVARTIS 3,000 1,000 1,000 0,000 0,000
DIA 2,000 NOVARTIS 1,000 1,000 1,000 0,000 0,000
DIA 3,000 NOVARTIS 1,000 1,000 0,000 0,000 0,000
DIA 4,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
DIA 5,000 NOVARTIS 0,000 0,000 0,000 0,000 0,000
DIA 6,000 NOVARTIS 0,000 0,000 0,000 0,000 0,000
DIA 1,000 NOVARTIS 3,000 1,000 1,000 0,000 0,000
DIA 2,000 NOVARTIS 1,000 1,000 1,000 0,000 0,000
DIA 3,000 NOVARTIS 1,000 1,000 0,000 0,000 0,000
DIA 4,000 NOVARTIS 2,000 2,000 0,000 0,000 0,000
DIA 5,000 NOVARTIS 2,000 0,000 0,000 0,000 0,000
DIA 6,000 NOVARTIS 0,000 0,000 0,000 0,000 0,000
DEHI 1,000 NOVARTIS 3,000 0,000 0,000 0,000 0,000
DEHI 2,000 NOVARTIS 2,000 0,000 0,000 0,000 0,000
DEHI 3,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
DEHI 4,000 NOVARTIS 0,000 0,000 0,000 0,000 0,000
DEHI 5,000 NOVARTIS 0,000 0,000 0,000 0,000 0,000
DEHI 6,000 NOVARTIS 0,000 0,000 0,000 0,000 0,000
DEHI 1,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
DEHI 2,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
DEHI 3,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
DEHI 4,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
1
TYPE
2
WEIGHT
3
TIAMULIN/PLAC
EBO
4
DAY1
5
DAY2
6
DAY3
7
DAY4
8
DAY5
9
DAY6
10
DAY7
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
DEHI 5,000 NOVARTIS 0,000 0,000 0,000 0,000 0,000
DEHI 6,000 NOVARTIS 0,000 0,000 0,000 0,000 0,000
DEHI 1,000 NOVARTIS 2,000 1,000 0,000 0,000 0,000
DEHI 2,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
DEHI 3,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
DEHI 4,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
DEHI 5,000 NOVARTIS 0,000 0,000 0,000 0,000 0,000
DEHI 6,000 NOVARTIS 0,000 0,000 0,000 0,000 0,000
DEHI 1,000 NOVARTIS 3,000 1,000 1,000 0,000 0,000
DEHI 2,000 NOVARTIS 3,000 2,000 0,000 0,000 0,000
DEHI 3,000 NOVARTIS 2,000 1,000 0,000 0,000 0,000
DEHI 4,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
DEHI 5,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
DEHI 6,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
DEHI 1,000 NOVARTIS 2,000 0,000 0,000 0,000 0,000
DEHI 2,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
DEHI 3,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
DEHI 4,000 NOVARTIS 0,000 0,000 0,000 0,000 0,000
DEHI 5,000 NOVARTIS 0,000 0,000 0,000 0,000 0,000
DEHI 6,000 NOVARTIS 0,000 0,000 0,000 0,000 0,000
DEHI 1,000 NOVARTIS 3,000 1,000 1,000 0,000 0,000
DEHI 2,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
DEHI 3,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
DEHI 4,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
DEHI 5,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
DEHI 6,000 NOVARTIS 0,000 0,000 0,000 0,000 0,000
APPE 1,000 NOVARTIS 3,000 1,000 0,000 0,000 0,000
APPE 2,000 NOVARTIS 2,000 1,000 1,000 0,000 0,000
APPE 3,000 NOVARTIS 1,000 1,000 0,000 0,000 0,000
APPE 4,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
APPE 5,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
APPE 6,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
APPE 1,000 NOVARTIS 1,000 1,000 0,000 0,000 0,000
APPE 2,000 NOVARTIS 1,000 1,000 0,000 0,000 0,000
APPE 3,000 NOVARTIS 1,000 0,000 1,000 0,000 0,000
APPE 4,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
APPE 5,000 NOVARTIS 0,000 0,000 0,000 0,000 0,000
APPE 6,000 NOVARTIS 0,000 0,000 0,000 0,000 0,000
APPE 1,000 NOVARTIS 2,000 1,000 0,000 0,000 0,000
APPE 2,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
APPE 3,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
APPE 4,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
APPE 5,000 NOVARTIS 0,000 0,000 0,000 0,000 0,000
APPE 6,000 NOVARTIS 0,000 0,000 0,000 0,000 0,000
APPE 1,000 NOVARTIS 3,000 1,000 1,000 0,000 0,000
APPE 2,000 NOVARTIS 3,000 2,000 0,000 0,000 0,000
1
TYPE
2
WEIGHT
3
TIAMULIN/PLAC
EBO
4
DAY1
5
DAY2
6
DAY3
7
DAY4
8
DAY5
9
DAY6
10
DAY7
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
APPE 3,000 NOVARTIS 2,000 1,000 0,000 0,000 0,000
APPE 4,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
APPE 5,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
APPE 6,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
APPE 1,000 NOVARTIS 2,000 0,000 0,000 0,000 0,000
APPE 2,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
APPE 3,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
APPE 4,000 NOVARTIS 0,000 0,000 0,000 0,000 0,000
APPE 5,000 NOVARTIS 0,000 0,000 0,000 0,000 0,000
APPE 6,000 NOVARTIS 0,000 0,000 0,000 0,000 0,000
APPE 1,000 NOVARTIS 3,000 1,000 1,000 0,000 0,000
APPE 2,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
APPE 3,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
APPE 4,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
APPE 5,000 NOVARTIS 1,000 0,000 0,000 0,000 0,000
APPE 6,000 NOVARTIS 0,000 0,000 0,000 0,000 0,000
DIA 1,000 BALCANPHARM 3,000 3,000 2,000 1,000 0,000
DIA 2,000 BALCANPHARM 3,000 2,000 2,000 0,000 0,000
DIA 3,000 BALCANPHARM 2,000 2,000 1,000 0,000 0,000
DIA 4,000 BALCANPHARM 1,000 1,000 1,000 0,000 0,000
DIA 5,000 BALCANPHARM 1,000 1,000 0,000 0,000 0,000
DIA 6,000 BALCANPHARM 1,000 1,000 0,000 0,000 0,000
DIA 1,000 BALCANPHARM 1,000 1,000 1,000 1,000 0,000
DIA 2,000 BALCANPHARM 1,000 1,000 1,000 1,000 0,000
DIA 3,000 BALCANPHARM 1,000 2,000 1,000 1,000 0,000
DIA 4,000 BALCANPHARM 1,000 0,000 0,000 0,000 0,000
DIA 5,000 BALCANPHARM 2,000 0,000 0,000 0,000 0,000
DIA 6,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
DIA 1,000 BALCANPHARM 1,000 1,000 1,000 0,000 0,000
DIA 2,000 BALCANPHARM 1,000 1,000 1,000 0,000 0,000
DIA 3,000 BALCANPHARM 1,000 1,000 0,000 0,000 0,000
DIA 4,000 BALCANPHARM 1,000 0,000 0,000 0,000 0,000
DIA 5,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
DIA 6,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
DIA 1,000 BALCANPHARM 3,000 3,000 1,000 1,000 0,000
DIA 2,000 BALCANPHARM 3,000 2,000 1,000 1,000 0,000
DIA 3,000 BALCANPHARM 3,000 2,000 1,000 1,000 0,000
DIA 4,000 BALCANPHARM 1,000 1,000 0,000 0,000 0,000
DIA 5,000 BALCANPHARM 1,000 1,000 0,000 0,000 0,000
DIA 6,000 BALCANPHARM 1,000 1,000 0,000 0,000 0,000
DIA 1,000 BALCANPHARM 1,000 1,000 1,000 0,000 0,000
DIA 2,000 BALCANPHARM 1,000 1,000 1,000 0,000 0,000
DIA 3,000 BALCANPHARM 1,000 1,000 0,000 0,000 0,000
DIA 4,000 BALCANPHARM 1,000 0,000 0,000 0,000 0,000
DIA 5,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
DIA 6,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
1
TYPE
2
WEIGHT
3
TIAMULIN/PLAC
EBO
4
DAY1
5
DAY2
6
DAY3
7
DAY4
8
DAY5
9
DAY6
10
DAY7
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
DIA 1,000 BALCANPHARM 1,000 1,000 1,000 0,000 0,000
DIA 2,000 BALCANPHARM 1,000 1,000 1,000 0,000 0,000
DIA 3,000 BALCANPHARM 1,000 1,000 0,000 0,000 0,000
DIA 4,000 BALCANPHARM 2,000 2,000 0,000 0,000 0,000
DIA 5,000 BALCANPHARM 2,000 0,000 0,000 0,000 0,000
DIA 6,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
DEHI 1,000 BALCANPHARM 3,000 1,000 1,000 0,000 0,000
DEHI 2,000 BALCANPHARM 2,000 1,000 0,000 0,000 0,000
DEHI 3,000 BALCANPHARM 1,000 0,000 0,000 0,000 0,000
DEHI 4,000 BALCANPHARM 1,000 0,000 0,000 0,000 0,000
DEHI 5,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
DEHI 6,000 BALCANPHARM 0,000 0,000 1,000 0,000 0,000
DEHI 1,000 BALCANPHARM 1,000 1,000 0,000 0,000 0,000
DEHI 2,000 BALCANPHARM 1,000 0,000 0,000 0,000 0,000
DEHI 3,000 BALCANPHARM 1,000 0,000 0,000 0,000 0,000
DEHI 4,000 BALCANPHARM 1,000 0,000 0,000 0,000 0,000
DEHI 5,000 BALCANPHARM 1,000 0,000 0,000 0,000 0,000
DEHI 6,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
DEHI 1,000 BALCANPHARM 1,000 1,000 0,000 0,000 0,000
DEHI 2,000 BALCANPHARM 1,000 1,000 0,000 0,000 0,000
DEHI 3,000 BALCANPHARM 1,000 1,000 0,000 0,000 0,000
DEHI 4,000 BALCANPHARM 1,000 1,000 0,000 0,000 0,000
DEHI 5,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
DEHI 6,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
DEHI 1,000 BALCANPHARM 3,000 1,000 0,000 0,000 0,000
DEHI 2,000 BALCANPHARM 2,000 0,000 0,000 0,000 0,000
DEHI 3,000 BALCANPHARM 1,000 0,000 0,000 0,000 0,000
DEHI 4,000 BALCANPHARM 1,000 0,000 0,000 0,000 0,000
DEHI 5,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
DEHI 6,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
DEHI 1,000 BALCANPHARM 1,000 1,000 0,000 0,000 0,000
DEHI 2,000 BALCANPHARM 1,000 0,000 0,000 0,000 0,000
DEHI 3,000 BALCANPHARM 1,000 0,000 0,000 0,000 0,000
DEHI 4,000 BALCANPHARM 1,000 0,000 0,000 0,000 0,000
DEHI 5,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
DEHI 6,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
DEHI 1,000 BALCANPHARM 1,000 0,000 0,000 0,000 0,000
DEHI 2,000 BALCANPHARM 1,000 0,000 0,000 0,000 0,000
DEHI 3,000 BALCANPHARM 1,000 0,000 0,000 0,000 0,000
DEHI 4,000 BALCANPHARM 2,000 1,000 0,000 0,000 0,000
DEHI 5,000 BALCANPHARM 2,000 1,000 0,000 0,000 0,000
DEHI 6,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
APPE 1,000 BALCANPHARM 3,000 2,000 1,000 0,000 0,000
APPE 2,000 BALCANPHARM 2,000 1,000 1,000 0,000 0,000
APPE 3,000 BALCANPHARM 2,000 1,000 0,000 0,000 0,000
APPE 4,000 BALCANPHARM 1,000 0,000 0,000 0,000 0,000
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4
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5
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6
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7
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8
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9
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10
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185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
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203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
APPE 5,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
APPE 6,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
APPE 1,000 BALCANPHARM 1,000 1,000 1,000 0,000 0,000
APPE 2,000 BALCANPHARM 1,000 0,000 0,000 0,000 0,000
APPE 3,000 BALCANPHARM 1,000 0,000 0,000 0,000 0,000
APPE 4,000 BALCANPHARM 1,000 0,000 0,000 0,000 0,000
APPE 5,000 BALCANPHARM 1,000 0,000 0,000 0,000 0,000
APPE 6,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
APPE 1,000 BALCANPHARM 1,000 1,000 1,000 0,000 0,000
APPE 2,000 BALCANPHARM 1,000 1,000 1,000 0,000 0,000
APPE 3,000 BALCANPHARM 1,000 1,000 0,000 0,000 0,000
APPE 4,000 BALCANPHARM 1,000 0,000 0,000 0,000 0,000
APPE 5,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
APPE 6,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
APPE 1,000 BALCANPHARM 3,000 1,000 0,000 0,000 0,000
APPE 2,000 BALCANPHARM 2,000 1,000 1,000 0,000 0,000
APPE 3,000 BALCANPHARM 2,000 1,000 0,000 0,000 0,000
APPE 4,000 BALCANPHARM 1,000 1,000 0,000 0,000 0,000
APPE 5,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
APPE 6,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
APPE 1,000 BALCANPHARM 1,000 1,000 0,000 0,000 0,000
APPE 2,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
APPE 3,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
APPE 4,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
APPE 5,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
APPE 6,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
APPE 1,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
APPE 2,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
APPE 3,000 BALCANPHARM 1,000 1,000 0,000 0,000 0,000
APPE 4,000 BALCANPHARM 1,000 1,000 0,000 0,000 0,000
APPE 5,000 BALCANPHARM 1,000 1,000 0,000 0,000 0,000
APPE 6,000 BALCANPHARM 0,000 0,000 0,000 0,000 0,000
DIA 1,000 PLACEBO 3,000 3,000 3,000 9,000 9,000 9,000 9,000
DIA 2,000 PLACEBO 3,000 3,000 3,000 2,000 2,000 3,000 3,000
DIA 3,000 PLACEBO 1,000 1,000 2,000 2,000 2,000 2,000 3,000
DIA 4,000 PLACEBO 1,000 1,000 1,000 1,000 2,000 2,000 2,000
DIA 5,000 PLACEBO 0,000 0,000 0,000 1,000 1,000 1,000 1,000
DIA 6,000 PLACEBO 0,000 0,000 0,000 0,000 0,000 1,000 1,000
DIA 1,000 PLACEBO 2,000 2,000 2,000 2,000 1,000
DIA 2,000 PLACEBO 2,000 2,000 1,000 2,000 2,000
DIA 3,000 PLACEBO 1,000 1,000 2,000 1,000 1,000
DIA 4,000 PLACEBO 0,000 0,000 1,000 1,000 1,000
DIA 5,000 PLACEBO 0,000 0,000 0,000 1,000 1,000
DIA 6,000 PLACEBO 0,000 0,000 0,000 0,000 0,000
DIA 1,000 PLACEBO 0,000 0,000 1,000 1,000 1,000
DIA 2,000 PLACEBO 2,000 2,000 1,000 2,000 2,000
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DIA 3,000 PLACEBO 1,000 1,000 2,000 1,000 1,000
DIA 4,000 PLACEBO 0,000 0,000 1,000 1,000 1,000
DIA 5,000 PLACEBO 0,000 0,000 0,000 1,000 1,000
DIA 6,000 PLACEBO 0,000 0,000 0,000 0,000 0,000
DIA 1,000 PLACEBO 2,000 2,000 2,000 2,000 3,000
DIA 2,000 PLACEBO 2,000 2,000 2,000 2,000 2,000
DIA 3,000 PLACEBO 1,000 1,000 2,000 1,000 1,000
DIA 4,000 PLACEBO 1,000 1,000 1,000 1,000 2,000
DIA 5,000 PLACEBO 0,000 0,000 0,000 1,000 1,000
DIA 6,000 PLACEBO 0,000 0,000 0,000 0,000 0,000
DIA 1,000 PLACEBO 1,000 2,000 2,000 2,000 3,000
DIA 2,000 PLACEBO 1,000 2,000 1,000 2,000 2,000
DIA 3,000 PLACEBO 1,000 1,000 2,000 1,000 1,000
DIA 4,000 PLACEBO 1,000 0,000 1,000 1,000 1,000
DIA 5,000 PLACEBO 0,000 0,000 0,000 1,000 1,000
DIA 6,000 PLACEBO 0,000 0,000 0,000 0,000 0,000
DIA 1,000 PLACEBO 0,000 0,000 1,000 1,000 1,000
DIA 2,000 PLACEBO 1,000 1,000 1,000 2,000 2,000
DIA 3,000 PLACEBO 1,000 1,000 1,000 1,000 1,000
DIA 4,000 PLACEBO 1,000 0,000 1,000 1,000 1,000
DIA 5,000 PLACEBO 0,000 0,000 0,000 1,000 1,000
DIA 6,000 PLACEBO 0,000 0,000 0,000 0,000 0,000
DEHI 1,000 PLACEBO 3,000 3,000 3,000 9,000 9,000
DEHI 2,000 PLACEBO 2,000 3,000 3,000 2,000 2,000
DEHI 3,000 PLACEBO 1,000 1,000 2,000 2,000 2,000
DEHI 4,000 PLACEBO 1,000 1,000 1,000 1,000 2,000
DEHI 5,000 PLACEBO 0,000 0,000 0,000 1,000 1,000
DEHI 6,000 PLACEBO 0,000 0,000 0,000 0,000 0,000
DEHI 1,000 PLACEBO 2,000 2,000 2,000 2,000 2,000
DEHI 2,000 PLACEBO 1,000 2,000 1,000 2,000 2,000
DEHI 3,000 PLACEBO 1,000 1,000 2,000 1,000 1,000
DEHI 4,000 PLACEBO 1,000 0,000 1,000 1,000 1,000
DEHI 5,000 PLACEBO 0,000 0,000 0,000 1,000 1,000
DEHI 6,000 PLACEBO 0,000 0,000 0,000 0,000 1,000
DEHI 1,000 PLACEBO 0,000 0,000 1,000 1,000 1,000
DEHI 2,000 PLACEBO 1,000 2,000 1,000 2,000 2,000
DEHI 3,000 PLACEBO 1,000 1,000 2,000 1,000 1,000
DEHI 4,000 PLACEBO 1,000 0,000 1,000 1,000 1,000
DEHI 5,000 PLACEBO 0,000 0,000 0,000 1,000 1,000
DEHI 6,000 PLACEBO 0,000 0,000 0,000 0,000 1,000
DEHI 1,000 PLACEBO 2,000 2,000 2,000 2,000 3,000
DEHI 2,000 PLACEBO 2,000 2,000 2,000 2,000 2,000
DEHI 3,000 PLACEBO 1,000 1,000 2,000 1,000 1,000
DEHI 4,000 PLACEBO 1,000 1,000 1,000 1,000 2,000
DEHI 5,000 PLACEBO 0,000 0,000 0,000 1,000 1,000
DEHI 6,000 PLACEBO 0,000 0,000 0,000 0,000 0,000
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DEHI 1,000 PLACEBO 2,000 2,000 2,000 2,000 3,000
DEHI 2,000 PLACEBO 2,000 2,000 1,000 2,000 2,000
DEHI 3,000 PLACEBO 1,000 1,000 2,000 1,000 1,000
DEHI 4,000 PLACEBO 0,000 0,000 1,000 1,000 1,000
DEHI 5,000 PLACEBO 0,000 0,000 0,000 1,000 1,000
DEHI 6,000 PLACEBO 0,000 0,000 0,000 0,000 0,000
DEHI 1,000 PLACEBO 0,000 0,000 1,000 1,000 1,000
DEHI 2,000 PLACEBO 1,000 1,000 1,000 2,000 2,000
DEHI 3,000 PLACEBO 1,000 1,000 1,000 1,000 1,000
DEHI 4,000 PLACEBO 1,000 0,000 1,000 1,000 1,000
DEHI 5,000 PLACEBO 0,000 0,000 0,000 1,000 1,000
DEHI 6,000 PLACEBO 0,000 0,000 0,000 0,000 0,000
APPE 1,000 PLACEBO 3,000 3,000 3,000 9,000 9,000
APPE 2,000 PLACEBO 2,000 2,000 3,000 2,000 2,000
APPE 3,000 PLACEBO 1,000 1,000 2,000 2,000 2,000
APPE 4,000 PLACEBO 0,000 1,000 1,000 1,000 2,000
APPE 5,000 PLACEBO 0,000 0,000 0,000 1,000 1,000
APPE 6,000 PLACEBO 0,000 0,000 0,000 0,000 0,000
APPE 1,000 PLACEBO 1,000 2,000 2,000 2,000 1,000
APPE 2,000 PLACEBO 1,000 2,000 1,000 2,000 2,000
APPE 3,000 PLACEBO 1,000 1,000 2,000 1,000 1,000
APPE 4,000 PLACEBO 1,000 0,000 1,000 1,000 1,000
APPE 5,000 PLACEBO 0,000 0,000 0,000 1,000 1,000
APPE 6,000 PLACEBO 0,000 0,000 0,000 0,000 0,000
APPE 1,000 PLACEBO 0,000 0,000 1,000 1,000 1,000
APPE 2,000 PLACEBO 1,000 2,000 1,000 2,000 2,000
APPE 3,000 PLACEBO 1,000 1,000 2,000 1,000 1,000
APPE 4,000 PLACEBO 1,000 0,000 1,000 1,000 1,000
APPE 5,000 PLACEBO 0,000 0,000 0,000 1,000 1,000
APPE 6,000 PLACEBO 0,000 0,000 0,000 0,000 0,000
APPE 1,000 PLACEBO 2,000 2,000 2,000 2,000 3,000
APPE 2,000 PLACEBO 2,000 2,000 2,000 2,000 2,000
APPE 3,000 PLACEBO 1,000 1,000 2,000 1,000 1,000
APPE 4,000 PLACEBO 1,000 1,000 1,000 1,000 2,000
APPE 5,000 PLACEBO 0,000 0,000 0,000 1,000 1,000
APPE 6,000 PLACEBO 0,000 0,000 0,000 0,000 0,000
APPE 1,000 PLACEBO 1,000 2,000 2,000 2,000 3,000
APPE 2,000 PLACEBO 1,000 2,000 1,000 2,000 2,000
APPE 3,000 PLACEBO 1,000 1,000 2,000 1,000 1,000
APPE 4,000 PLACEBO 1,000 0,000 1,000 1,000 1,000
APPE 5,000 PLACEBO 0,000 0,000 0,000 1,000 1,000
APPE 6,000 PLACEBO 0,000 0,000 0,000 0,000 0,000
APPE 1,000 PLACEBO 0,000 0,000 1,000 1,000 1,000
APPE 2,000 PLACEBO 1,000 1,000 1,000 2,000 2,000
APPE 3,000 PLACEBO 1,000 1,000 1,000 1,000 1,000
APPE 4,000 PLACEBO 1,000 0,000 1,000 1,000 1,000
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APPE 5,000 PLACEBO 0,000 0,000 0,000 1,000 1,000
APPE 6,000 PLACEBO 0,000 0,000 0,000 0,000 0,000
